The Top 5 Analyst Questions From AdaptHealth’s Q1 Earnings Call

AdaptHealth’s first quarter was driven by the rapid onboarding of a large capitated contract, which involved transitioning hundreds of thousands of patients to its platform. Management noted this was the largest such operational undertaking in home medical equipment history. However, the quarter was also marked by elevated labor costs associated with the accelerated transition, leading to a miss on profit metrics. CEO Suzanne Foster described the performance as a “monumental quarter,” but acknowledged the operational complexity and added costs, stating, “the extra implementation spend was the right decision for the relationship and the patients.”

Is now the time to buy AHCO? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From AdaptHealth’s Q1 Earnings Call

• Pito Chickering (Deutsche Bank) asked about the sustainability of organic growth excluding capitated arrangements and received confirmation from CFO Jason Clemens that core business growth was just over 4% with expectations for acceleration as new contracts are fully realized.
• Kevin Caliendo (UBS) questioned the drivers behind expected EBITDA margin improvements beyond labor normalization. Clemens cited better collections and the scaling of AI initiatives, while CEO Suzanne Foster explained that AI-led efficiencies would show more financial impact in 2027.
• Michael Murray (RBC Capital Markets) pressed on the long-term margin outlook, asking if a sustained low-20% EBITDA margin was achievable. Clemens stated the target is attainable as capitated contracts mature and cost controls solidify.
• Brian Tanquilut (Jefferies) inquired about the operational milestones enabling rapid rollout of new de novo locations. Foster detailed that duplicative onboarding in different regions caused labor inefficiencies, which should subside now that the transition is complete.
• Richard Close (Canaccord Genuity) asked about investment needs for future capitated contracts, with Clemens explaining upfront CapEx is needed for new markets, but future deals should be less capital-intensive due to AdaptHealth’s expanded infrastructure.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the normalization of labor costs and realization of margin improvement as the new capitated contract matures, (2) the pace at which AI and digital initiatives drive operational efficiency and patient engagement, and (3) the announcement and successful onboarding of additional capitated agreements. Execution in the Diabetes Health segment and ongoing asset portfolio optimization will also remain key areas of focus.

AdaptHealth currently trades at $11.37, down from $13.04 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.